Mylan-Biocon Bags FDA Nod for Biosimilar Drug ‘Fulphila’, Reduces Infection Risk in Cancer Patients

US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.